11.32
-0.32 (-2.72%)
| Penutupan Terdahulu | 11.64 |
| Buka | 11.53 |
| Jumlah Dagangan | 218,783 |
| Purata Dagangan (3B) | 483,150 |
| Modal Pasaran | 521,926,880 |
| Harga / Jualan (P/S) | 5.10 |
| Harga / Buku (P/B) | 19.27 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 12 May 2025 - 16 May 2025 |
| Margin Keuntungan | -140.35% |
| Margin Operasi (TTM) | -108.11% |
| EPS Cair (TTM) | -2.96 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 4.40% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 481.07% |
| Nisbah Semasa (MRQ) | 6.01 |
| Aliran Tunai Operasi (OCF TTM) | -96.77 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -46.83 M |
| Pulangan Atas Aset (ROA TTM) | -25.78% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | UroGen Pharma Ltd. | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 5.0 |
| Purata | 2.38 |
|
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 8.40% |
| % Dimiliki oleh Institusi | 86.98% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 55.00 (HC Wainwright & Co., 385.74%) | Beli |
| Median | 25.00 (120.79%) | |
| Rendah | 16.00 (Goldman Sachs, 41.31%) | Pegang |
| Purata | 30.00 (164.95%) | |
| Jumlah | 4 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 10.68 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| D. Boral Capital | 28 Apr 2025 | 25.00 (120.79%) | Beli | 11.26 |
| 13 Mar 2025 | 25.00 (120.79%) | Beli | 10.90 | |
| HC Wainwright & Co. | 28 Apr 2025 | 55.00 (385.74%) | Beli | 11.26 |
| 11 Mar 2025 | 55.00 (385.74%) | Beli | 10.82 | |
| Goldman Sachs | 17 Apr 2025 | 16.00 (41.31%) | Pegang | 9.67 |
| Scotiabank | 16 Apr 2025 | 23.00 (103.13%) | Beli | 10.39 |
| Ladenburg Thalmann | 19 Feb 2025 | 31.00 (173.78%) | Beli | 10.82 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |